Catasys Announces Transition to a New Board of Directors

           Catasys Announces Transition to a New Board of Directors

PR Newswire

LOS ANGELES, Feb. 13, 2014

LOS ANGELES, Feb. 13, 2014 /PRNewswire/ --Catasys, Inc. (OTC BB: CATS),
provider of proprietary health management services to health insurers and
employers, today announced the transition to a new Board of Directors.

Terren Peizer, Chairman and CEO of Catasys, commented, "The purpose of our
transition is to have a new invigorated board, which more accurately reflects
our shareholder base, our stage of development, and increases our public
company experience with the addition of C level management and directors that
serve other similar situated public companies. The transition also increases
our healthcare services industry relationships and expertise with proven
healthcare executives that know the Company's target market."

The new board additions include:

  oMinal Patel, MD: Dr. Patel is an Executive Vice President at iHealth
    Technologies. He joined iHealth in 2012 through its acquisition of Care
    Management International (CMI), an innovative care management company that
    Dr. Patel founded and served as CEO. Prior to this, he has served in
    several executive roles, most recently as President and COO of Horizon
    Healthcare of New York, a 200,000 member subsidiary of Horizon Blue Cross
    Blue Shield of New Jersey and prior to that he was the Executive Medical
    Director for Quality Management and Clinical Innovations for Horizon
    BCBSNJ. He was also previously a strategy consultant for McKinsey and
    Company. Dr. Patel has a BS in medical sciences and a doctorate in
    medicine from Boston University and a Masters in Public Health degree from
    Harvard University.
  oRichard Berman: Mr. Berman is currently the President and CEO of LICAS, a
    K-12, College and University, Health Care consulting firm. In addition, he
    currently serves as Chairman of Emblem Health' s Quality of Care Committee
    and a member of its Audit Committee. Previously he was a management
    consultant for McKinsey & Company, Executive Vice President of NYU Medical
    Center and Professor of Health Care Management at the NYU School of
    Medicine. He has also held various roles at Korn Ferry International,
    Howe-Lewis International, the New York Office of Health Systems
    Management, US Department of Health Education, and Welfare, and as the
    President of Manhattanville College. In 1995, Mr. Berman was selected by
    Manhattanville College to serve as its tenth President. Mr. Berman is
    credited with the turnaround of the College, where he served until 2009.
    In 2006, Mr. Berman was awarded a Fulbright Commission grant to travel to
    Uganda and provide strategic planning and leadership training to Kabale
    University. Mr. Berman has a Bachelors of Business Administration, a MBA
    and Masters in Public Health. 
  oSteven Kriegsman: Mr. Kriegsman has been CytRx's (Nasdaq: CYTR) President
    and Chief Executive Officer and director since July 2002. He also serves
    as a director of Galena Biopharma, Inc. (Nasdaq: GALE) and Chairman of
    Galena's Compensation and Transaction Committees. He previously served as
    Director and Chairman of Global Genomics from June 2000. Mr. Kriegsman is
    an inactive Chairman and Founder of Kriegsman Capital Group LLC, a
    financial advisory firm specializing in emerging growth companies in the
    healthcare industry. He previously served as a Director and is the former
    Chairman of the Audit Committee of Bradley Pharmaceuticals, Inc. (NYSE,
    the company since has been sold). Mr. Kriegsman has a BS degree with
    honors from New York University in Accounting.
  oDavid Smith: Mr. Smith is the President, Chief Executive Officer and
    Chief Investment Officer of the Trading Advisor. Mr. Smith was the
    founder and Chief Executive Officer of Coast Asset Management. Mr. Smith
    has worked in various capacities in the securities industry, including as
    Vice President of Security Pacific Bank,and Oppenheimer and Company as a
    bond arbitrageur, and he is also a successful investor in small cap growth
    companies. Mr. Smith has a M.B.A. from the University of California at
  oMarvin Ingelman: Mr. Ingelman is Chief Executive Officer of Sprylogics
    International Inc. (SPY: TSX), a leader in the semantic search technology
    sector and currently on the Board of Directors of Jamba Juice (JMBA :
    NASDAQ) and American Apparel, Inc. (APP : NYSE MKT). Previously he was
    CEO of Unomobile, Inc., a mobile advertising and messaging platform that
    was acquired in February 2010 by Poynt Corporation. Mr Ingelman was also
    founder, President and CEO of Brandera Inc., which operated, a leading online business-to-business site for the Graphic
    Arts and creative community, and has served as a business development
    consultant for numerous technology companies, and established a number of
    other successful ventures.

Mr. Peizer concluded, "We are delighted to add the new Board Members with such
strong credentials to Catasys' Board. Their proven backgrounds in driving
growth and creating shareholder value will be an asset to the company and its
shareholders as we continue to add on new health plans and other payors to our
OnTrak healthcare solution."

About Catasys, Inc.

Catasys, Inc. provides specialized health management services to health plans
and employers through a network of licensed and company managed health care
providers. The Catasys substance dependence program improves member health,
thereby lowering overall costs. The proprietary program addresses substance
dependence as a chronic disease, focusing on the whole health of the member.
The program delivers integrated medical and psychosocial interventions in
combination with long-term care coaching. For further information, please

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press
release are forward-looking and made pursuant to the Safe Harbor provisions of
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements reflect numerous assumptions and involve a variety of risks and
uncertainties, many of which are beyond our control that may cause actual
results to differ materially from stated expectations. These risk factors
include, among others, changes in regulations or issuance of new regulations
or interpretations, limited operating history, lack of outcomes and
statistically significant formal research studies, difficulty enrolling
members in our programs, the risk that treatment programs might not be
effective, difficulty in developing, exploiting and protecting proprietary
technologies and intense competition and substantial regulation in the health
care industry. You are urged to consider statements that include the words
"may," "will," "would," "could," "should," "believes," "estimates,"
"projects," "potential," "expects," "plan," "anticipates," "intends,"
"continues," "forecast," "designed," "goal," or the negative of those words
and other comparable words to be uncertain and forward-looking. For a further
list and description of the risks and uncertainties we face, please refer to
our most recent Securities and Exchange Commission filings which are available
on its website at Such forward-looking statements are
current only as of the date they are made, and we assume no obligation to
update any forward-looking statements, whether as a result of new information,
future events or otherwise.

SOURCE Catasys, Inc.

Contact: James Carbonara, Hayden IR, 646-755-7412,
Press spacebar to pause and continue. Press esc to stop.